Effective November 29, 2022, Viatris completed the sale of substantially all of its biosimilars portfolio (including related product trademarks) to Biocon Biologics Limited and its subsidiaries (“Biocon”) and the relevant marketing authorizations are in process of being transferred. Viatris Inc. and its subsidiaries (“Viatris”) are not affiliates of Biocon but are providing certain transition services to Biocon following the transaction completion date, such as operating websites (including this site) relating to the biosimilars portfolio on Biocon’s behalf.
VIATRISTM offers a savings program for SEMGLEE and Insulin Glargine (insulin glargine-yfgn) injection. These savings cards help eligible patients who have commercial health insurance save on out-of-pocket costs.
This savings card is not available to uninsured patients or patients
who are
covered by a state or federal funded healthcare program.
Restrictions apply. Please see full terms and conditions here.
Since 2013, the list prices of some insulins have skyrocketed in the United States. People who do not have health insurance, or those who are on high-deductible insurance plans, may have to pay out-of-pocket costs up to $1,000 for a one-month supply of insulin.2
There are many organizations with a mission to help patients and caregivers affected by diabetes.
Scroll down to learn more about two of them, GetInsulin.org and Beyond Type 1, which may help you connect with outreach programs, community platforms, and financial assistance options.2
Please select from the following:
(This information also applies to Insulin Glargine (insulin glargine-yfgn) injection)
What is SEMGLEE (insulin glargine-yfgn) injection 100 Units/mL?
SEMGLEE is a prescription long-acting man-made-insulin used to control high blood sugar in adults and children with type 1 diabetes and in adults with type 2 diabetes.
It is not known if SEMGLEE is safe and effective in children less than 6 years of age with type 1 diabetes.